38 slides from Evolus, Inc. Common Stock's earnings presentation, Aug 5, 2026
Slide 1: Evolus
eCVOLUS in -volus
Slide 2: Investor Presentation August 2026
INVESTOR PRESENTATION AUGUST 2026 2
Slide 3: Disclosures: Forward Looking Statements
DISCLOSURES FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future resul
Slide 4: Performance Beauty
PERFORMANCE QUALITY SAFETY INNOVATION EFFICACY BEAUTY ACCESSIBLE BEAUTY EXPERIENCE CREATIVE EXPRESSION 4
Slide 5: A Compelling Investment Opportunity
A COMPELLING INVESTMENT OPPORTUNITY EVOLYSSE®: POSITIONED FOR UNDERPENETRATED MULTI-YEAR GROWTH AESTHETICS MARKET Launched in U.S. in Q2 2025 and in Europe Supports long-term growth in Q2 2026 Cash-pay business model with a MILLENNIALS ANCHORING DEMAND1 DIGITAL FIRST PLATFORM Reshaping aesthetics in
Slide 6: Differentiated Portfolio Combines Beauty First Toxin With First New HA Technology
DIFFERENTIATED PORTFOLIO COMBINES A FAST-GROWING BEAUTY FIRST TOXIN WITH THE FIRST NEW HA TECHNOLOGY IN A DECADE Proven Performance with proven safety in 5 clinical First HA Made with Cold-X® Technology which uses studies and the largest Phase 3 study against near-freezing temperatures designed to p
Slide 7: A More Diversified and Scaling Portfolio
A MORE DIVERSIFIED AND SCALING PORTFOLIO U.S. Portfolio Expansion with Three Injectable Verticals Supported by a Pipeline That Will Deliver Three New Products Over The Next Four Years • A scaled neurotoxin foundation with Jeuveau® , which has achieved 14% market share across more than 18,000 account
Slide 8: Large & Underpenetrated Markets
GROWING OUR NEUROTOXIN PRESENCE IN LARGE & UNDERPENETRATED MARKETS EVOLUS IS LAUNCHED IN THE MARKETS WITH THE JEUVEAU® SHARE OF U.S. NEUROTOXIN MARKET BIGGEST OPPORTUNITY OVER THE LAST FEW YEARS* 16% 14% 14% 12% 13% 10% 11% 8% 9% 6% 7% 7% 4% 4% 2% 0% 2019 2020 2021 2022 2023 2024 2025 U.S. Launched
Slide 9: Long Term Global Aesthetic Market Is a Growth Market
LONG TERM GLOBAL AESTHETIC MARKET IS A GROWTH MARKET UNDERLYING DEMAND FOR AESTHETIC PROCEDURES REMAINS RESILIENT WITH DERMAL FILLER MARKET EXPERIENCING CORRECTION FILLERS $6.5B NEUROTOXINS $5.7B $2.2B $3.7B $2.2B $1.8B $4.3B $3.5B $1.9B 2019 2025 2028 7% CAGR 4% CAGR Sources: Medical Insight’s The
Slide 10: Strong Historical Revenue Growth
STRONG HISTORICAL REVENUE GROWTH CONSISTENTLY OUTPACING THE MARKET WITH DOUBLE-DIGIT REVENUE GROWTH FOR SIX CONSECUTIVE YEARS ~40% CAGR $297.2M $266.3M $202.1M $148.6M $99.7M $56.5M 2020 2021 2022 2023 2024 2025 10
Slide 11: A Performance Beauty Platform
STRUCTURAL CUSTOMER ADVANTAGE PARTNERSHIP Cash-pay model Co-branded marketing, enables scale and education, and training profitability aligned to practice economics and commercial success LEADING DIGITAL CONSUMER ECOSYSTEM LOYALTY + Integrated digital platform FREQUENCY that simplifies operations, R
Slide 12: Differentiated Cash Pay Business Model
DIFFERENTIATED CASH PAY BUSINESS MODEL WHY CASH PAY? Supports value proposition by: • Eliminating third-party reimbursement complexity • Delivering flexible, customer-driven pricing • Enabling scalable co-branded marketing partnerships • Driving consumer demand directly to our customers • Building d
Slide 13: Co-Branded Marketing That Empowers Customers
CO-BRANDED MARKETING THAT EMPOWERS CUSTOMERS 400M+ IMPRESSIONS FROM 2025 CAMPAIGNS OUT-OF-HOME ADVERTISING PAID SOCIAL ADS STREAMING TV INFLUENCER CONTENT CREATION 13
Slide 14: A Medical Education Platform That Supports Customers
A MEDICAL EDUCATION PLATFORM THAT SUPPORTS CUSTOMERS IN 2025: LIVE EVENTS EVOLUS ACADEMY MEDICAL AFFAIRS TEAM TRAINING BUS 300+ EDUCATED 6K+ INJECTORS EDUCATED 14K+ INJECTORS 70 CITIES & 55+ CLINIC EVENTS 14
Slide 15: Digital Capabilities Bridging Customer and Consumer Engagement
DIGITAL CAPABILITIES BRIDGING CUSTOMER AND CONSUMER ENGAGEMENT CONNECTS CUSTOMERS Simplifies AND CONSUMERS PURCHASING AND through digital engagement INVENTORY MANAGEMENT PROVIDES DASHBOARDS Activates co-branded media to & METRICS BUILD AWARENESS AND to measure what matters DRIVE DEMAND ENABLES PRICI
Slide 16: Modern Loyalty Program
MODERN LOYALTY PROGRAM Evolux® is Evolus’ portfolio-wide loyalty program that rewards customers for purchasing across Jeuveau® and Evolysse® with transparent pricing benefits and increased co-branded media support based on their total combined spend.
Slide 17: A Digitally Native, Growing Millennial Consumer Base
A DIGITALLY NATIVE, GROWING MILLENNIAL CONSUMER BASE DRIVING LONG TERM DEMAND • More likely to engage through mobile-first experiences • High quality expectations support premium, branded aesthetics • Self-care orientation drives repeat, preventative treatments • Social connectivity accelerates awar
Slide 18: Demand Shifting Toward Millennials and Gen Z
DEMAND SHIFTING TOWARD MILLENNIALS AND GEN Z PROJECTED SHARE OF AESTHETICS PATIENTS BY GENERATION ADOPTION AMONG 4% GEN Z & YOUNGER 10% THE MILLENNIAL & 25% ≥1997 YOUNGER 35% DEMOGRAPHIC: MILLENNIAL 1981- 1996 AT LEAST 2X 40% GEN X AS LIKELY AS THE 1965 - 1980 36% OLDER DEMOGRAPHIC 31% BOOMER & OLDE
Slide 19: Digital Loyalty Platform Driving New Consumer Starts and Repeat Engagement
DIGITAL LOYALTY PLATFORM THAT DRIVES NEW CONSUMER STARTS AND REPEAT ENGAGEMENT INSTANT EASY CO-BRANDED t Text Message Today 9:41 AM Nice work! Your specialist should now be providing you with a $40 discount on your treatment today. 19 19
Slide 20: Rewards Engagement Is Scaling With Repeat Usage
REWARDS ENGAGEMENT IS SCALING WITH REPEAT USAGE DRIVING INCREASED CONSUMER LOYALTY EVOLUS REWARDS ENROLLMENTS EXISTING PATIENTS DRIVE A GROWING SHARE OF SURPASSED 1.5 MILLION IN Q2 2026 REWARDS REDEMPTIONS REINFORCING LOYALTY1 >1.5M 5000 TOTAL CONSUMER REDEMPTIONS (000s) 70% >1.3M >1.4M >1.3M EXISTI
Slide 21: Market Expansion Opportunity—Fillers
MARKET EXPANSION OPPORTUNITY—FILLERS TOXINS AND FILLERS ARE THE TOP 2 MEDICAL AESTHETIC PROCEDURES FILLERS ARE THE #2 SERVICE PROVIDED FILLERS ARE THE #1 ADD-ON PROCEDURE ACROSS ALL CHANNELS FOR TOXIN USERS 1 2 FILLER 48% PLASTIC TOXINS FILLERS SURGEONS: SKINCARE 18% SKIN DERMATOLOGISTS: TOXINS FILL
Slide 22: Evolysse: An Innovative Technology That Complements the Jeuveau Brand
EVOLYSSE AN INNOVATIVE TECHNOLOGY ® THAT COMPLEMENTS THE JEUVEAU BRAND ® 22
Slide 23: Symatese Science Genesis
SYMATESE SCIENCE GENESIS 25+ YEARS IN R&D AND MANUFACTURING OF AESTHETICS & MEDICAL BIOMATERIALS LAUNCHED FIRST PEROUSE PLASTIE LAUNCH OF 2 PRODUCTS: BREAST IMPLANTS NEVELIA®, DERMAL HEMOTESE® & SOLD TO MENTOR REGENERATION COLLAPAT®II MATRIX 1997 2003 2004 2007 2011 2013 2021 SOLD RIGHTS OF XpresHAn
Slide 24: First HA Injectable Innovation Breakthrough in a Decade
FIRST HA INJECTABLE INNOVATION BREAKTHROUGH IN A DECADE HYLACROSS® OBT® COLD-X® TECHNOLOGY TECHNOLOGY TECHNOLOGY 1996 2000 2005 2008 2015 2025 NASHA® VYCROSS® PNT® TECHNOLOGY TECHNOLOGY TECHNOLOGY 24 Note: Based on the first regulatory approval date for each technology
Slide 25: Evolysse Manufacturing
EVOLYSSE® MANUFACTURING COLD-X® TECHNOLOGY BY SYMATESE CROSS-LINKING HA CONDITIONS • Typical cross-linking: Heat • Cold-X® cross-linking: Cold DESIGNED TO CREATE A MORE NATURAL INJECTABLE HA GEL • Cross-linking technology o Preserve the hyaluronic acid chain o Decrease fragmentation o Less BDDE is r
Slide 26: Evolysse Versatility: Indications
EVOLYSSE® VERSATILITY INDICATIONS • INDICATIONS RECEIVED FDA APPROVAL LAUNCHED IN U.S. Q2 2025 2026 | Q4 APPROVAL (EXPECTED) 2027 | APPROVAL (EXPECTED) 26
Slide 27: Profhilo
PROFHILO® THE GOLD STANDARD THAT DEFINES SKIN QUALITY IN EUROPE A CATEGORY-LEADING BRAND EXPANDS EVOLUS INTO A DISTINCT THIRD INJECTABLE VERTICAL 70+ 4.8M+ 2015 81% 86% COUNTRIES TREATMENTS GLOBAL OF HCPS SATISFIED/ OF PATIENTS SATISFIED/ WORLDWIDE LAUNCH VERY SATISFIED VERY SATISFIED CATEGORY-DEFIN
Slide 28: GLP-1 Adoption: A Durable Tailwind for Aesthetics
GLP-1 ADOPTION: A DURABLE TAILWIND FOR AESTHETICS WEIGHT LOSS ADOPTION IS EXPANDING THE PATIENT FUNNEL AND CREATING NEW, VISIBLE NEEDS ACROSS FACIAL VOLUME, SKIN LAXITY, AND SKIN QUALITY 1 in 7 70% $2.0B U.S. adults had taken a GLP-1 of providers plan to increase projected 2030 market for drug by Ju
Slide 29: Evolus Is Uniquely Positioned for the GLP-1 Opportunity
EVOLUS IS UNIQUELY POSITIONED FOR THE GLP-1 OPPORTUNITY A COMPLEMENTARY INJECTABLE PORTFOLIO CAN ADDRESS THE PRINCIPAL FACIAL EFFECTS OF WEIGHT LOSS ACROSS EXPRESSION, STRUCTURE, AND SKIN QUALITY TOXIN FILLER SKIN Jeuveau® treats dynamic lines, an Evolysse® restores facial volume Profhilo® adds a fu
Slide 30: Financials
lov 2volus FINANCIALS
Slide 31: Q2 2026 Results
Q2 2026 RESULTS Q2 NET REVENUE DELIVERED THIRD CONSECUTIVE QUARTER OF $84.1M PROFITABILITY 1 AND RAISED FULL-YEAR 2026 FINANCIAL OUTLOOK $84.1M NET REVENUE, UP 21% Y-O-Y $69.4M • Continued momentum of Jeuveau® $66.9M • Continued ramp of Evolysse® • Continued strength in international markets • Launc
Slide 32: Accelerating Operating Leverage
DOUBLE-DIGIT TOTAL REVENUE GROWTH WITH A LARGELY FLAT COST BASE DRIVES NET REVENUE ACCELERATING OPERATING LEVERAGE +11% - +13% IN 2026: 11% – 13% PROJECTED DOUBLE DIGIT REVENUE GROWTH $330M- $337M $297.2M MINIMAL ADJUSTED 1% – 3% $266.3M OPERATING EXPENSE GROWTH $202.1M $148.6M LOW – $99.7M ADJUSTED
Slide 33: Expanding Operating Leverage
EXPANDING OPERATING LEVERAGE • Consistent operating leverage delivered through 2024 • 2025 reflected a planned investment year with the addition of Evolysse®, marking the evolution to a multi-product portfolio • Beginning in 2026, with the portfolio foundation in place, Evolus is positioned to deliv
Slide 34: FY 2026 Outlook
FY 2026 OUTLOOK UPDATED GUIDANCE AND EXPECTATIONS: • Raises total net revenues for the full-year 2026 to between $330 million and $337 million, from $327 million to $337 million, which represents 11% to 13% growth over the prior year. • Raises adjusted gross profit margin for the full-year 2026 to b
Slide 35: Long-Term Outlook
lov 2volus LONG-TERM OUTLOOK
Slide 36: 2028 Long-Term Outlook
REFLECTING: • A recalibrated aesthetic market outlook given current market conditions and a more conservative near-term growth environment 2028 LONG-TERM • Strengthened market share, driven by continued outperformance, portfolio expansion, and commercial OUTLOOK PROJECTING execution • International
Slide 37: Thank You
@VOLUS THANK YOU
Slide 38: Non-GAAP Information
NON-GAAP INFORMATION Within this presentation, “profitability” is defined as achieving positive adjusted EBITDA. This presentation includes references to non-GAAP operating expenses, non-GAAP operating income (loss), and non-GAAP operating income margin which each exclude (i) the revaluation of cont